Table 2.
The general pathologic characteristics of primary SCC/ASC patients and HCC patents
| Primary SCC/ASC group | HCC group | χ 2 /F/ t | P | |
|---|---|---|---|---|
| Patients | 9 | 40 | - | - |
| Tumor capsule | ||||
| Yes | 0 | 30(75%) | 14.392 | 0.000 |
| No | 9(100%) | 10(25%) | ||
| Macrovascular invasion | ||||
| Yes | 0 | 3(7.5%) | 0.006 | 0.937 |
| No | 9(100%) | 37(92.5%) | ||
| Microvascular invasion | ||||
| Yes | 2(22.2%) | 40 | 30.222 | 0.000 |
| No | 7(77.8%) | 0 | ||
| Lymph node metastasis | ||||
| Yes | 4(44.4%) | 7(17.5%) | 1.712 | 0.191 |
| No | 5(55.6%) | 33(82.5%) | ||
| Histologic grade (Edmondson-Steiner) | 4.060 | 0.044 | ||
| I | 0 | 0 | ||
| II | 6(66.7%) | 10(25%) | ||
| III | 3(33.3%) | 30(75%) |